Market Data 
Markets
Explore small cap ideas before they hit the headlines.
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
July 1, 2026 9:00 AM
PR Newswire (Canada)
Issued on behalf of MindWalk Holdings Corp.
MindWalk Holdings Corp. (NASDAQ: HYFT) filed a foundational European patent application covering the multi-dimensional data architecture at the core of its HYFT® Technology, an attempt to protect, at the architectural level, the enriched biological data layer that its commercial platforms run on.
NEW YORK, July 1, 2026 /CNW/ -- USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that lasting competitive advantage is shifting away from the model and toward the proprietary, structured data a model reasons over. On that thesis, MindWalk Holdings Corp. (NASDAQ: HYFT) has just made a defining move, filing a foundational European patent application covering the multi-dimensional data structure at the core of its proprietary HYFT® Technology.
Key Takeaways
Patenting the Moat, Not the Model
There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable. As frontier systems from competing labs converge on similar capabilities, the place where lasting competitive advantage accrues is shifting, away from the model and toward the proprietary, structured data the model is given to reason over. On that thesis, MindWalk Holdings Corp. (NASDAQ: HYFT) has just made a defining move: the Austin-based Bio-Native AI company announced it filed a foundational patent application with the European Patent Office (Application No. EP26187897.9) covering the multi-dimensional data structure at the heart of its proprietary HYFT® Technology.
The intent, in the company's framing, is to protect at the architectural level the enriched biological representation that underpins its commercial platform, the asset MindWalk regards as its core, compounding competitive advantage. In other words, rather than racing to build a better model, MindWalk is moving to fence off the data layer beneath the models. The company's position is blunt: the competitive question in its market is not which AI model a customer runs, because every model trends toward commodity, it is what the model runs on.
What the Patent Actually Describes
The application, titled "Hyperdimensional Vector Data Structures for Biological Subsequences and Property Inference," describes a specific and unusual approach to organizing biological data. In conventional pipelines, sequence identity, learned embeddings, and biological annotations are scattered across separate tables that must be joined together at the moment of a query. MindWalk's structure instead encodes each short biological subsequence together with the properties that define its behavior, as coordinates of a single object in a space of at least 2,000 dimensions.
Per the filing, that single self-contained object carries a biological subsequence alongside at least 50 heterogeneous properties, including structural data, microenvironmental geometry, functional annotations, contextual associations, and metadata. The application further describes a database of at least 600 million such records, and a method that performs vector-space operations across them to infer additional biological properties. A central claimed concept the company calls the "reduced combinatory number" identifies the subsequences most constrained in their biological context, and therefore the most informative to store and analyze. The practical claim is that the indexable unit is itself biologically meaningful, rather than an opaque vector, which, MindWalk argues, is what allows AI models and autonomous agents to reason over biology reliably rather than guess at it.
The company is careful to define the architecture by what it is not: it describes the approach as alignment-free and not dependent on any single AI model, and distinct from a sequence-alignment system, a k-mer index, a motif library, or an embedding-only method, each of which, in its telling, discards either biological meaning or semantic structure. The distinction the filing is meant to protect is that its indexable unit carries both.
Why the Data Layer Is Where Value Is Migrating
The strategic logic tracks a broader shift in enterprise AI. When any well-funded competitor can license or build a capable model, the model stops being a differentiator. What cannot be easily replicated is a deep, structured, domain-specific dataset built over many years, the context that makes a general model useful in a specialized field. MindWalk says it spent more than two decades curating exactly such a layer for the life sciences, and the patent filing is the move to make that architecture defensible rather than merely valuable.
The market context the company cites is substantial. By MindWalk's account, drawing on third-party estimates, spending on AI in drug discovery is projected to grow from roughly US$5 billion in 2026 to more than US$8 billion by 2030, and that spend sits atop the more than US$250 billion the pharmaceutical industry invests in research and development each year. The company is positioning its data layer as infrastructure beneath that spending. As with any market-sizing, those figures are third-party projections that may prove inaccurate, and the company flags them as context only.
How the Patent Connects to Revenue
The filing is not an abstract science-project claim; it sits directly beneath products the company is already commercializing. The same enriched representation powers ReefIQ™, which MindWalk describes as a biological context layer for life sciences, and the LensAI™ platform that runs on it for target discovery, candidate diligence, and portfolio decision support, the kind of agentic AI workflows pharmaceutical companies are racing to deploy. Critically, the company states that LensAI is already in contracted, recurring arrangements with life-sciences customers today. The patent is intended to place foundational IP protection around the layer those deployments depend on, an asset MindWalk says compounds in analytical value as more data accumulates on the platform.
By the company's description, its HYFT® Technology underpins a continuously evolving biological representation of roughly 660 million biological patterns and 25 billion relationships, refined over 20 years of curation, that enriches data at ingestion. The filing follows MindWalk's June 2026 launch of ReefIQ and, the company says, extends a deliberate strategy of making the biological representation, not any individual AI model, the durable, compounding asset.
The Public Company Cohort Investors Are Watching
MindWalk would be an unusual pure-play on the "data layer" thesis, but several public life-sciences AI companies illustrate the broader move toward proprietary data and platform moats. These comparisons are for context only; each company pursues a different technology and business model, several are far larger or further along, and none is a proxy for MindWalk or implies any partnership or comparable performance. Tempus AI (NASDAQ: TEM) is the closest thematic mirror: its competitive advantage rests on a proprietary multimodal clinical-and-molecular dataset measured in hundreds of petabytes, and it has reported strong net revenue retention as biopharma customers build on that data, a real-world example of data-as-moat in life sciences. AbCellera (NASDAQ: ABCL) runs an antibody-discovery platform monetized across a large base of partnered programs, illustrating the platform-and-partnership model rather than a single-drug bet.
Schrödinger (NASDAQ: SDGR) approaches the field from physics-based computational simulation, combining a software platform used by thousands of researchers with its own drug-development programs, the established, software-led end of the spectrum. And Recursion (NASDAQ: RXRX) is among the most visible "TechBio" names, pairing large proprietary experimental datasets and an AI platform with major pharma collaborations and an internal clinical pipeline, while remaining clinical-stage and pre-profit. Together these names sketch a sector being repriced around proprietary data, platforms, and partnerships, the same terrain MindWalk's patent filing stakes a claim on, even as each company's outcome rests on its own execution.
The Bottom Line
A patent application is a beginning, not a guarantee. European examination can narrow or reject claims, and the scope, issuance, and enforceability of any patent that ultimately issues remain open questions the company itself flags. But the strategic signal is clear and coherent: MindWalk is betting that in a world of commodity AI models, the lasting value in life-sciences AI lives in the structured biological data underneath, and it is moving to protect its version of that layer at the architectural root. For investors tracking where durable advantage accrues as the AI buildout matures, MindWalk's filing is a concrete data point in a much larger debate, with the patent's prosecution, customer adoption, and revenue trajectory the markers worth watching from here.
SIGNAL OVER NOISE
Signal over noise. Biotech, artificial-intelligence, and drug-discovery headlines move fast, and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.
CONTACT
USA News Group
SOURCES
[1] MindWalk Holdings Corp., "MindWalk Files Foundational Patent on the Multi-Dimensional Data Architecture at the Core of HYFT® Technology" (Business Wire, 2026; EPO Application No. EP26187897.9; ReefIQ/LensAI; 660M patterns / 25B relationships).
[2] Tempus AI, Inc. (NASDAQ: TEM), Form 8-K and 2025 results (data-and-applications business, net revenue retention), 2026.
[3] AbCellera Biologics Inc. (NASDAQ: ABCL), corporate and partnership disclosures, 2026.
[4] Schrödinger, Inc. (NASDAQ: SDGR), platform and pipeline disclosures, 2026.
[5] Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Q1 2026 results and corporate disclosures, 2026.
[6] AI-in-drug-discovery market estimates (Fortune Business Insights; Astute Analytica) and pharmaceutical R&D spending (Fierce Biotech; Statista), cited for context.
DISCLAIMER
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by USA News Group on behalf of Market IQ Media Group Limited, a company incorporated under the laws of Ireland ("MIQL"). MIQL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQL and its owner/operators do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQL has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements, including statements regarding European patent application No. EP26187897.9 and the prosecution, scope, issuance, enforceability, and competitive value of any patent that may issue; the role of the patented architecture in HYFT® Technology, ReefIQ™, and the LensAI™ platform; the size, growth, and addressability of the markets referenced; the pace and degree of customer and market adoption of the Company's infrastructure; and the technical performance of AI-based discovery methods. Forward-looking statements are subject to known and unknown risks and uncertainties, including that patent claims may be narrowed, rejected, or successfully challenged; that third-party market estimates may prove inaccurate; and competitive, regulatory, technical, and capital-markets risks, that could cause actual results to differ materially. Additional information is available in MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, the Company undertakes no obligation to update any forward-looking statement. References to other companies are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance. HYFT® is a registered trademark, and LensAI™ and ReefIQ™ are trademarks, of MindWalk Holdings Corp. or its subsidiaries.
View original content to download multimedia:https://www.prnewswire.com/news-releases/as-ai-models-become-commodities-one-bio-native-ai-company-just-moved-to-patent-the-thing-that-actually-compounds-the-data-302815033.html
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
June 30, 2026 9:00 AM
PR Newswire (US)
Issued on behalf of GT Biopharma, Inc.
GT Biopharma, Inc. (NASDAQ: GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications expanding beyond oncology.
USA News Group News Commentary
NEW YORK, June 30, 2026 /PRNewswire/ -- Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a recent update from GT Biopharma, Inc. (NASDAQ: GTBP), a clinical-stage immuno-oncology company built around its proprietary natural killer (NK) cell engager platform. On June 1, 2026, the company said it has implemented artificial-intelligence-based tools across its discovery and protein-engineering work, and that the resulting efficiency gains are expected to push multiple new development candidates into pre-IND development in 2027.
Key Takeaways
Putting AI to Work on the Hardest Part of Drug Design
The core of the announcement is that GT Biopharma is using AI not as a marketing veneer but at the bench, in the actual design of its molecules. According to the company, AI-guided sequence and structural analyses are used to identify new candidate tumor-targeting engagers and multi-domain proteins with favorable binding, stability, and developability profiles, allowing the team to prioritize early on the molecules most likely to succeed beyond the discovery stage. In a field where the overwhelming majority of early candidates fail, screening computationally before committing lab resources is where time and money are saved.
The company describes the tools doing more than just screening. They are also used to inform rational engineering, optimizing the orientation of protein domains, the design of the linkers that connect them, and the overall spatial architecture of a molecule, with the goals of enhancing binding, supporting productive immune-synapse formation, and minimizing structural liabilities that can hurt potency, manufacturability, or consistency. In downstream work, AI-based structural modeling is applied to predict surface exposure, steric compatibility, and assay performance, helping refine constructs before resource-intensive laboratory and animal studies. The throughline is the same: do more of the hard thinking in silico, so that the expensive, slow physical experiments are reserved for the most promising designs.
What GT Biopharma Actually Builds: the TriKE Platform
To understand why this matters for GT Biopharma specifically, it helps to know what the company makes. GT Biopharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE® NK cell engager platform. As the company describes it, the TriKE® platform is designed to harness and enhance the cancer-killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology.
Designing these multi-domain proteins is exactly the kind of complex, multi-variable engineering problem where computational tools can have an outsized effect. Each TriKE has to bind the right targets with the right strength, fold and remain stable, manufacture consistently, and form a functional connection between immune cell and tumor. Optimizing all of those properties at once, by hand and by trial and error, is painstaking. That is the work GT Biopharma now says it is accelerating with AI.
A Bridge to the Clinical Story
The discovery update does not exist in isolation. It comes as GT Biopharma advances two TriKE candidates through Phase 1 clinical trials. GTB-3650 is being evaluated in patients with relapsed or refractory CD33-expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. GTB-5550, which targets the protein B7-H3 on solid tumors, received FDA clearance of its investigational new drug application earlier in 2026, and the company announced that its first patient was dosed in the Phase 1 dose-escalation basket trial in May 2026. Executive Chairman and CEO Michael Breen tied the two threads together, stating that as the company continues "to demonstrate clinical execution acumen with GTB-3650 and GTB-5550 advancing through Phase 1 this year, we are now looking forward to our next-generation assets with potential for shorter development timeliness, increased probability of clinical success, and lower development costs in the coming years."
Breen also characterized the shift in plain terms, saying the company has "seen a marked acceleration in our discovery productivity following recent initiatives implementing AI-based technologies, which have been adapted to improve our drug engineering capabilities." In other words, the message to investors is that the same company executing in the clinic today is simultaneously trying to build a deeper, cheaper, faster-moving pipeline behind those lead programs.
The Honest Risk Picture
None of this removes the substantial risks that come with a micro-cap, clinical-stage biotech, and GT Biopharma is candid about them in its own disclosures. Pre-IND candidates targeted for 2027 are early, and AI-assisted design does not guarantee a molecule will prove safe or effective in humans. The company's forward-looking statements explicitly flag its ability to continue as a going concern, its need for additional capital, the possibility of clinical-trial delays, the risk that products fail to meet safety or efficacy endpoints, and the risk that its common stock could be delisted if it cannot maintain listing requirements. As of its first-quarter 2026 report, the company described a cash position in the single-digit millions, sufficient by its own account to fund operations into the latter part of the year. That financing reality is the central caveat for any investor, and it is characteristic of the high-risk, binary nature of early-stage drug development, where most candidates that enter trials never reach approval.
The Public Companies Around the Theme
GT Biopharma sits within a broader field of companies pursuing NK-cell, immune-engager, and AI-driven approaches to drug development. These names are referenced for context only; each pursues a different strategy, sits at a different stage, several are far larger and better capitalized, and none is a proxy for GT Biopharma or implies any partnership or comparable outcome. Nkarta (NASDAQ: NKTX) is a dedicated NK-cell therapy developer that has increasingly oriented its engineered NK candidates toward autoimmune disease as well as cancer, underscoring the same "beyond oncology" potential GT Biopharma references. Fate Therapeutics (NASDAQ: FATE) is among the more established NK and induced-pluripotent-stem-cell platform companies, representing the better-resourced end of the cell-therapy spectrum.
Compass Therapeutics (NASDAQ: CMPX) offers a window into the broader bispecific and immune-engager landscape, developing antibody-based therapeutics that direct immune activity against tumors; while its modalities differ from TriKE, it belongs to the same conceptual family of engager formats and recently reported a stronger balance sheet and late-stage data progress. Recursion (NASDAQ: RXRX) approaches the theme from the AI angle that GT Biopharma's update highlights, pairing large proprietary datasets and machine learning with drug discovery and major pharmaceutical partnerships, while remaining clinical-stage and pre-profit. Together these names illustrate two powerful currents, NK-directed immunotherapy and AI-enabled drug design, converging on the same goal of better, faster, cheaper medicines, even as each company's fate rests on its own science and execution.
The Bottom Line
GT Biopharma's AI update is not a clinical result, and it should not be mistaken for one. What it represents is a strategic bet that the company can use modern computational tools to build its next wave of candidates faster and at lower cost, behind two clinical programs already moving through Phase 1. For a capital-constrained micro-cap, efficiency in discovery is not a luxury but a survival strategy, and the promise of pre-IND candidates in 2027 gives investors a concrete future marker to track. Whether the AI-driven approach translates into better molecules and, ultimately, successful therapies remains to be proven in the lab and the clinic. For now, the markers worth watching are the continued progress of GTB-3650 and GTB-5550 through Phase 1, the company's financing path, and the first evidence that its AI-designed candidates can advance as promised. More detail is available in the company's June 1, 2026 announcement.
SIGNAL OVER NOISE
Signal over noise. Biotech, immuno-oncology, and AI-drug-discovery headlines move fast, and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.
CONTACT
USA News Group
info@usanewsgroup.com
SOURCES
[1] GT Biopharma, Inc. (NASDAQ: GTBP), "GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives" (GlobeNewswire, June 1, 2026). Available at: https://www.gtbiopharma.com/news-media/press-releases/detail/310/gt-biopharma-provides-update-on-pipeline-discovery.
[2] GT Biopharma, Inc., "GT Biopharma Reports First Quarter 2026 Financial Results" (May 15, 2026; cash position, GTB-3650 Cohort 4, pipeline updates).
[3] GT Biopharma, Inc., "First Patient Dosed in Phase 1 Trial of GTB-5550" (May 14, 2026) and "FDA Clearance of IND for GTB-5550" (February 3, 2026).
[4] Nkarta, Inc. (NASDAQ: NKTX), Q1 2026 results and corporate highlights (engineered NK therapies; autoimmune focus), May 12, 2026.
[5] Fate Therapeutics, Inc. (NASDAQ: FATE), corporate and pipeline disclosures, 2026.
[6] Compass Therapeutics, Inc. (NASDAQ: CMPX), Q1 2026 results (~US$209M cash; tovecimig Phase 2/3 data), May 5, 2026.
[7] Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), corporate and AI-platform disclosures, 2026.
DISCLAIMER
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
USA News Group is a wholly-owned subsidiary of Market IQ Media Group Limited, accompany incorporated under the laws of Ireland ("MIQL"). This article is being distributed by ISA News Group on behalf of MIQL. MIQL has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQL does not own shares of GT Biopharma, Inc. but reserves the right to buy and sell shares of GT Biopharma, Inc. at any time without any further notice. There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of GT Biopharma, Inc. by CDMG; this is a digital media distribution.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. Forward-looking statements regarding exploration, development, clinical, regulatory, production, and market outcomes are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements, including statements regarding the expected benefits of GT Biopharma's AI-based discovery and engineering initiatives; the anticipation of multiple new development candidates entering pre-IND development in 2027; the potential expansion of targets and indications beyond oncology; the progress, timing and results of the GTB-3650 and GTB-5550 Phase 1 clinical trials; and the Company's development plans and cost and timeline expectations. Forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially, including, as the Company has disclosed, its ability to continue as a going concern; its need for additional capital and the uncertainty of obtaining it; the risk of clinical-trial delays; the risk that product candidates fail to achieve necessary safety and efficacy endpoints; the risk that the Company's common stock could be delisted if it fails to maintain listing requirements; and other factors detailed in the Company's filings with the SEC at www.sec.gov, including its most recent Form 10-K and subsequent Form 10-Q reports. AI-assisted design does not ensure that any candidate will prove safe or effective or receive regulatory approval. References to other companies are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance. TriKE® is a registered trademark of GT Biopharma, Inc. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made; the publisher undertakes no obligation to update or revise them except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/a-clinical-stage-cancer-company-is-putting-ai-to-work-designing-its-next-generation-of-tumor-targeting-drugs-302814371.html
Interestingly, within the past two weeks at least five directors have set up rule 10b5-1 trading plans.
Why is that interesting? Besides everyone doing it more or less at the same time, this trading plan establishes a clear defense against any allegations of insider trading.
Why would these people feel that such a thing might be of concern? They're expecting some significant incoming gains from stock holdings...and they wish to protect those gains.
Sounds reasonable. Invest wisely.
THV
Bearish Signal Reversed since 6 Jan 2026. GLTA
Nice analyst upgrade $10-$11
4.99 ...https://www.globenewswire.com/news-release/2025/12/08/3201434/0/en/index.html· 7m23minsRecursion Pharmaceuticals(RXRX.US)4.7104.939-4.27%+4.86%
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP).Through an unbiased phenotypic screen of thousands of compounds, the earliest version of the Recursion OS identified selective MEK1/2 inhibition as a highly specific mechanism capable of reversing APC loss-of-function signatures. Using high-content cellular phenomics driven by AI, REC-4881 emerged as one of the strongest phenotypic rescue hits, reverting APC-deficient cells toward a healthy state and suppressing ERK/MAPK hyperactivation downstream of APC loss. Guided by this AI-driven insight, Recursion and redirected REC-4881—originally evaluated clinically in solid tumors—as a mechanistically aligned therapeutic candidate for FAP. REC-4881 is now the first MEK1/2 inhibitor ever studied clinically for this disease."The durable polyp burden reduction demonstrated by REC-4881—especially the sustained effect seen at Week 25, 12 weeks after completing therapy—is highly encouraging for the FAP community," said Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine, and Principal Investigator of the TUPELO study. "Given the near-100% lifetime risk of colorectal cancer and the absence of any approved medical therapies, patients today often face a lifetime of intensive surveillance and life-altering surgeries. These Phase 2 results provide a meaningful basis for hope and support the potential for REC-4881 to offer a much-needed non-surgical option for this debilitating, life-long disease.""These Phase 2 results mark a meaningful validation of the Recursion OS," said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. "An unbiased phenotypic insight from our platform and driven by AI—linking MEK1/2 inhibition to APC loss-of-function biology—has now translated into rapid, substantial, and durable reductions in polyp burden in patients. This is a powerful example of how even the earliest versions of the Recursion OS can uncover therapeutic opportunities in diseases with no approved pharmacotherapy options. And since this discovery, we've only added to the breadth, depth, and power of the Recursion OS; we believe this is the first of many potential medicines that will advance as our flywheel of discovery accelerates."In the Phase 2 portion of the study, REC-4881 demonstrated rapid and durable reductions in polyp burden, with 43% median reduction in evaluable patients after 12 weeks of treatment. 75% of evaluable patients had a reduction in polyp burden in this same period. Importantly, the effect persisted well beyond the dosing period: 82% of evaluable patients (9 of 11) maintained reductions at Week 25—12 weeks after stopping therapy—with a 53% median decrease from baseline. These results are especially meaningful when considered alongside real-world natural history analyses showing that untreated FAP patients are expected to experience increases when left untreated."This program reflects a full validation cycle of the Recursion OS: an unbiased phenotypic signal identifying MEK1/2 inhibition as a rescue mechanism for APC loss-of-function, followed by mechanistic confirmation, clinical translation, and now encouraging human data in a disease with no approved medical therapies," said Najat Khan, Ph.D., Chief R&D and Commercial Officer and incoming President and CEO. "REC-4881, an allosteric MEK1/2 inhibitor, represents a first precision-medicine approach for the causal biology of FAP. In TUPELO, we are seeing rapid, substantial, and durable reductions in polyp burden — including sustained benefit after patients stop therapy. Equally important, our ClinTech and real-world data capabilities have been instrumental in guiding this program — from refining eligibility to contextualizing a single-arm dataset with a first-of-its-kind natural history study."About FAP
Next week, it will likely push through $7 again. Trouble is, swing it or hold for gold since their physical trial data could likely being positive will push it double digits.The earnings report we may see revenues increase again, while net earnings will likely be negative. If they beat Q2's net earnings per share $-0.42, that would look positive. Good luck with $RXRX👍 Its wild horse
In Double Top Breakout mode since Oct-1-2025. GLTA
RXRX should benefit of latest executive order UNLOCKING CURES FOR PEDIATRIC CANCER WITH ARTIFICIAL INTELLIGENCE
https://www.whitehouse.gov/presidential-actions/2025/09/unlocking-cures-for-pediatric-cancer-with-artificial-intelligence/
Yes! Exciting one to be in. Cathie Woods w/ ARK Investment owns 20% of$RXRX at $6 range. NVDA has a nice stake in it too. At these pps levels, i am bullish
Double Top Breakout on 18-Sep-2025. GLTA
|
Followers
|
35
|
Posters
|
|
|
Posts (Today)
|
1
|
Posts (Total)
|
212
|
|
Created
|
12/07/21
|
Type
|
Free
|
| Moderators | |||
Featured News
Sponsored
U.S. stocks closed lower on Wednesday, giving back an early rally as investors weighed soft private-sector hiring data and a lack of fresh guidance from Federal Reserve Chair Kevin Warsh on the path of interest rates. The pullback came a day after major indexes wrapped up their strongest quarter since 2020, and traders spent the […]
